NeoGenomics is a premier brand in the field of cancer diagnostics, pharma services, and information services. For over 18 years, NeoGenomics has been dedicated to serving oncologists, pathologists, pharmaceutical companies, and academic centers in their mission to provide better futures for individuals living with cancer. Their team of physicians, scientists, and laboratory professionals work collaboratively with cancer care teams to deliver crucial oncology answers that transform patients' lives.

With a comprehensive menu of traditional and state-of-the-art testing options, NeoGenomics supports a personalized approach to diagnostics, ensuring tailored and targeted testing for patients at every stage of their treatment journey. Additionally, NeoGenomics offers pharma services and data services to address the pressing challenges faced by patients and their care teams. Their expertise and resources enable the identification of patient cohorts, optimization of clinical trial design, and improvement of drug development.

NeoGenomics aims to provide precise diagnostic testing, facilitate the development of new therapies, and enable precision oncology care. With CAP-accredited and CLIA-certified facilities in the U. S